



Order: SAMPLE REPORT

Client #: 12345 Doctor: Sample Doctor, MD Doctors Data Inc. 3755 Illinois Ave. St. Charles, IL 60174 Patient: Sample Report Age: 57 Sex: Female Body Mass Index (BMI): N/A Menopausal Status: Post-Menopausal

Sample Collection	Date/Time
Date Collected	10/01/2018
AM30	10/01/2018 0800
Noon	10/01/2018 1200
Evening	10/01/2018 1700
Night	10/01/2018 2100
Date Received	10/03/2018
Date Reported	10/05/2018


Analyte	Result	Unit	L	WRI	Н	Optimal Range	Reference Interval
Cortisol AM30	11	nmol/L	$\diamond$			14.0 - 25.0	5.1 - 30.0
Cortisol Noon	4.7	nmol/L	$\diamond$			5.0 - 10.0	2.1 - 14.0
Cortisol Evening	2.5	nmol/L		$\diamond$		2.0 - 5.0	1.5 - 8.0
Cortisol Night	0.80	nmol/L	$\diamond$			1.0 - 4.0	0.33 - 7.0
DHEA*	181	pg/mL		$\diamond$			106 - 300

## Cortisol Graph



## Hormone Comments:

The suboptimal diurnal cortisol pattern and reported symptoms are consistent with evolving (Phase 2) HPA axis (adrenal gland) dysfunction.



## Notes:

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

\*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Methodology: Enzyme Immunoassay





Order: SAMPLE REPORT

Client #: 12345 Doctor: Sample Doctor, MD Doctors Data Inc. 3755 Illinois Ave. St. Charles, IL 60174 Patient: Sample Report Age: 57 Sex: Female Body Mass Index (BMI): N/A Menopausal Status: Post-Menopausal 
 Sample Collection
 Date/Time

 Date Collected
 10/01/2018

 AM30
 10/01/2018
 0800

 Noon
 10/01/2018
 1200

 Evening
 10/01/2018
 1700

 Night
 10/01/2018
 2100

 Date Received
 10/03/2018
 100

 Date Reported
 10/05/2018
 100

Analyte	Result	Unit	L	WRI	н	Reference Interval	Supplementation Range**
Estradiol (E2)	0.85	pg/mL		$\diamond$		0.5 - 3.2	1.5 - 7.2
Progesterone (Pg)	27	pg/mL		$\diamond$		18 - 126	500 - 3000
Pg/E2 Ratio	31.8		+			200 - 600	
Testosterone	82	pg/mL				6.0-49	30 - 60
DHEA*	181	pg/mL				106 - 300	



## Hormone Comments:

- Suboptimal estradiol is consistent with the reported deficiency symptoms. Progesterone to estradiol (Pg/E2) ratio and reported symptoms are
  consistent with progesterone insufficiency (estrogen dominance). Supplementation with topical progesterone to correct this relative deficiency is
  a consideration.
- The elevated testosterone is suggestive of metabolic syndrome (insulin resistance), although exogenous exposure (not reported) cannot be excluded. Serum vitamin D, hemoglobin A1c and insulin testing may be warranted.

Notes:

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

The Pg/E2 ratio is an optimal range established based on clinical observation. Progesterone supplementation is generally required to achieve this level in men and postmenopausal women.

\*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

\*\*If supplementation is reported then the supplementation ranges will be graphed. The supplementation ranges depicted are for informational purposes only and were derived from a cohort of adult men and women utilizing physiologic transdermal bioidentical hormone therapy.

Methodology: Enzyme Immunoassay